Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and Rani Therapeutics (NASDAQ:RANI – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.
Valuation and Earnings
This table compares Madrigal Pharmaceuticals and Rani Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Madrigal Pharmaceuticals | $958.40 million | 12.88 | -$288.28 million | ($12.89) | -41.47 |
| Rani Therapeutics | $4.88 million | 24.08 | -$29.67 million | ($0.27) | -3.12 |
Insider & Institutional Ownership
98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its stock price is 198% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Madrigal Pharmaceuticals and Rani Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Madrigal Pharmaceuticals | 1 | 2 | 15 | 0 | 2.78 |
| Rani Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
Madrigal Pharmaceuticals presently has a consensus price target of $699.64, indicating a potential upside of 30.90%. Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 938.45%. Given Rani Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Madrigal Pharmaceuticals.
Profitability
This table compares Madrigal Pharmaceuticals and Rani Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Madrigal Pharmaceuticals | -25.32% | -56.65% | -25.53% |
| Rani Therapeutics | N/A | -104.60% | -65.17% |
Summary
Rani Therapeutics beats Madrigal Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
